Orin
ECLNYSE·Chemicals - Specialty

Ecolab Inc. ECL

Market cap $77.7BP/E 36.7× trailingGross margin 44.1%Reports Tue 27 Oct, before the open
$276.00
+0.63 (+0.23%)live 11:25 ET
52-wk $243.15 – $309.27
Watch
Orin's take
0.62conviction · moderate
Refreshed 25 Aug · take v7. A new filing or a print queues the next refresh.

Operating margin expansion to 18.11% in FY2025 from 16.6% in FY2024, the $4.75B CoolIT acquisition opening AI data-center cooling exposure, and a raised 2026 outlook have driven a 12.2% three-month rally — but at 38.3x trailing P/E (63.3% above the peer median of 23.4x) and 26.8x EV/EBITDA (87.2% above peers), the stock prices in near-flawless execution while FY2025 EPS dipped to $7.28 from $7.37 and total debt climbed to $9.43B from $8.28B. With smart money at a modest 0.1338 score as of Q2 2026 and the CEO selling 17,862 shares at $280.14 on Aug 18, 2026, the risk/reward is balanced; hold for evidence that CoolIT integration and debt management justify the premium or for a valuation pullback.

What could go wrong

  • Valuation premium. At 38.3x P/E and 26.8x EV/EBITDA — 63.3% and 87.2% above the peer median respectively — any earnings disappointment or guidance cut could trigger a sharp de-rating.
  • Debt burden. Total debt rose to $9.43B in FY2025 from $8.28B in FY2024, and the $4.75B CoolIT acquisition adds further financing costs that could pressure net income, which already declined -1.74% in FY2025.
  • Revenue growth deceleration. Revenue growth slowed to 2.16% in FY2025 from 2.75% in FY2024 and 7.98% in FY2023, and a premium multiple requires sustained acceleration to justify it.
  • Insider selling. Recent open-market sales by the CEO (17,862 shares at $280.14), Co-COO (4,567 shares at $285.13), and CFO (3,357 shares at $276.96) in August 2026 signal limited insider conviction at current levels despite net buying of $6,222,783.98 over 24 months.

What would change my mind

CoolIT integration milestones. Evidence of revenue synergies or cost savings from CoolIT within the first two quarters post-closebullish
Leverage reduction. Total debt declines meaningfully from $9.43B through free cash flow deployment or asset salesbullish
Revenue reacceleration. Organic revenue growth reaccelerates above the 2.16% FY2025 pace, particularly in High-Tech and Life Sciences segmentsbullish
Valuation compression without earnings growth. P/E remains above 35x while EPS growth fails to resume, suggesting the premium is not justifiedbearish

Where this comes from: FMP derived_metrics FY2025 vs FY2024 · Zacks news article 2026-08-18 · Zacks news article 2026-08-18 · FMP peer_relative. Orin's read on ECL; not advice.

Twelve months actual closes to 2026-09-24 · actual filings

Sept 25Nov 25Jan 26Mar 26May 26Jul 26

50-day average 200-day average · volume below

Largest holders · 13F Q2 2026

Money flow
FilerPositionOf fund
Brasada Capital Management$9.5B1.7% of fund
Vanguard Capital Management$4.6B0.1% of fund
Jpmorgan Chase &$4.1B0.2% of fund
State Street$3.3B0.1% of fund
Morgan Stanley$2.2B0.1% of fund
Vanguard Portfolio Management$1.8B0.1% of fund

109 filers · quarter ended Q2 2026 · positions, not flows

Insiders, last 24 months: 210 Form 4 filings, net $7.2M. Of the 50 on hand, 4 were open-market purchases and 5 sales— the rest are grants, option exercises and tax withholding.

Ask Orin about ECL

its filings · its transcripts · its numbers

Orin answers questions about ECL from its filings, transcripts and numbers — with the source behind every claim. Your own desk starts with 3 free days, card required.

Start 3 free days →

Where it trades

vs its own 5y · Basic Materials
MetricNowOwn medianSector
P/E36.7×38.0×29.8×
EV/EBITDA25.8×21.2×—
P/S4.60×4.23×—
P/B7.7×7.6×—

Its P/E sits 40th percentile of its own last 5 years (−0.47σ from its own mean).

What the price assumes

17.4%

free-cash-flow growth every year for 10 years, discounted at 10%, is what today’s price implies — starting from $1.9B of trailing free cash flow. It is an assumption the market is making, not a forecast Orin is making.

What Wall Street published

37 firms · 2026-09-24
Consensus target

$326

$275 – $360 · +18% against today's price

How they rate it
  • 29 buy or overweight
  • 7 hold
  • 1 underweight or sell

The analysts’ consensus and their own ratings, not Orin’s. A target is a twelve-month opinion published by the firm that wrote it.

Against the companies it is compared to

median P/E 29.3× of 5 peers
CompanyMarket capP/EEV/EBITDAGrossNetROE
ECLEcolab Inc.$77B36.7×25.8×44.1%12.6%21%
APDAir Products and Chemicals, Inc.$63B—62.1×32.1%-0.4%-0%
CRHCRH plc$56B18.9×12.6×39.4%13.7%14%
FCXFreeport-McMoRan Inc.$104B35.5×12.2×26.8%11.4%15%
HWKNHawkins, Inc.$3B32.6×16.6×22.3%7.3%15%
NEMNewmont Corporation$128B15.3×8.6×54.5%38.1%25%
SHWThe Sherwin-Williams Company$78B29.3×20.6×49.1%11.0%62%

The median is of the 5 peers listed above and nothing else — check it against the column. This company trades 25.5% above it. The peer set is the vendor’s, so a company can appear here that a person would not have chosen.

What it has traded at

P/E by fiscal year
FY14 26.1×FY25 35.8×

What its sector has traded at

Basic Materials
FY14 23.8×FY26 28.6×

Two scales, drawn separately on purpose: a sector median and one company’s multiple are not the same number and putting them on one axis invites a comparison neither series supports.

Discounted cash flow

not recomputed since
ModelFair valueAgainstComputed
Standard DCF$222$258.57 · −14%2026-06-10
Levered DCF$182$258.57 · −30%2026-06-10

The vendor’s intrinsic-value models. Treat them as a low-growth anchor — for a fast grower the market routinely pays well above a DCF. These were computed against the price in the “against” column, not today’s.

Every estimate on one scale

price $276.00
52-week range$243 – $309
Analyst targets$275 – $360
Standard DCF$222 as of 2026-06-10, when it was $258.57
Levered DCF$182 as of 2026-06-10, when it was $258.57
At own 5y-median P/E (38×)$285
At 5y P/E range (32–59×)$237 – $446
At sector P/E (30×)$223

The vertical rule is the current price. Ranges and point estimates are the backend’s, published as they were calculated; an arrow means the estimate sits beyond this scale, and its number is on the right.